Literature DB >> 31745967

Expression of glucose-regulated protein 78 as prognostic biomarkers for triple-negative breast cancer.

Chenlian Yang1, Zhiwei Zhang2, Yutian Zou3, Guanfeng Gao3, Lingrui Liu3, Haifan Xu4, Feng Liu5.   

Abstract

INTRODUCTION: Glucose-regulated protein78(GRP78) is a stress - induced endoplasmic reticulum chaperone protein. it is closely related to the occurrence, development, proliferation, differentiation and drug resistance of breast cancer. However, the association and clinicopathological features between GRP78 and triple negative breast cancer (TNBC) remain to be studied.
MATERIAL AND METHODS: Clinical and pathological characteristics and overall survival were analysed retrospectively in 179 surgically resected TNBC patients. GRP78 was detected by immunohistochemistry (IHC) using breast cancer tissue microarrays (TMAs), and the association between GRP78 levels and clinicopathological factors and prognosis was analyzed. Furthermore, GRP78 expression in human TNBC and NTNBC cell lines was detected by Western blot and qRT-PCR. After Si-GRP78 knocked-down GRP78 in MDA-MB-231 and BT549 cell lines, cell proliferation was detected using Cell Counting Kit-8 (CCK-8) and cell colony formation was detected by crystal violet staining, respectively.
RESULTS: GRP78 was expressed in triple negative breast cancer (TNBC). GRP78 expression was significantly associated with invasive, distant metastasis and proliferation of TNBC (P<0.05). In addition, patients with positive GRP78 expression had shorter overall survival (OS) and disease-free survival (DFS). And the high expression of GRP78 was significantly associated with disease-free survival (DFS) in patients with TNBC (P<0.001).
CONCLUSIONS: These findings improve our understanding of the expression pattern of GRP78 in TNBC and clarify the role of GRP78 as promising prognostic biomarkers for triple-negative breast cancer.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31745967     DOI: 10.14670/HH-18-185

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  47 in total

1.  Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.

Authors:  Robert W Carlson; D Craig Allred; Benjamin O Anderson; Harold J Burstein; Stephen B Edge; William B Farrar; Andres Forero; Sharon Hermes Giordano; Lori J Goldstein; William J Gradishar; Daniel F Hayes; Clifford A Hudis; Steven Jay Isakoff; Britt-Marie E Ljung; David A Mankoff; P Kelly Marcom; Ingrid A Mayer; Beryl McCormick; Lori J Pierce; Elizabeth C Reed; Mary Lou Smith; Hatem Soliman; George Somlo; Richard L Theriault; John H Ward; Antonio C Wolff; Richard Zellars; Rashmi Kumar; Dorothy A Shead
Journal:  J Natl Compr Canc Netw       Date:  2012-07-01       Impact factor: 11.908

2.  CD5L is upregulated in hepatocellular carcinoma and promotes liver cancer cell proliferation and antiapoptotic responses by binding to HSPA5 (GRP78).

Authors:  Gemma Aran; Lucía Sanjurjo; Cristina Bárcena; Marina Simon-Coma; Érica Téllez; Maria Vázquez-Vitali; Marta Garrido; Laura Guerra; Esther Díaz; Isabel Ojanguren; Felix Elortza; Ramon Planas; Margarita Sala; Carolina Armengol; Maria-Rosa Sarrias
Journal:  FASEB J       Date:  2018-02-20       Impact factor: 5.191

3.  Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer.

Authors:  Y-W Chang; C-F Tseng; M-Y Wang; W-C Chang; C-C Lee; L-T Chen; M-C Hung; J-L Su
Journal:  Oncogene       Date:  2015-06-29       Impact factor: 9.867

Review 4.  Pharmacological effectors of GRP78 chaperone in cancers.

Authors:  Christian Bailly; Michael J Waring
Journal:  Biochem Pharmacol       Date:  2019-03-01       Impact factor: 5.858

Review 5.  Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.

Authors:  Carey K Anders; Lisa A Carey
Journal:  Clin Breast Cancer       Date:  2009-06       Impact factor: 3.225

Review 6.  Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer.

Authors:  A U Buzdar
Journal:  Ann Oncol       Date:  2009-01-15       Impact factor: 32.976

7.  PRDM14 directly interacts with heat shock proteins HSP90α and glucose-regulated protein 78.

Authors:  Chiharu Moriya; Hiroaki Taniguchi; Satoru Nagatoishi; Hisayoshi Igarashi; Kouhei Tsumoto; Kohzoh Imai
Journal:  Cancer Sci       Date:  2017-12-28       Impact factor: 6.716

Review 8.  GRP78 at the Centre of the Stage in Cancer and Neuroprotection.

Authors:  Caty Casas
Journal:  Front Neurosci       Date:  2017-04-05       Impact factor: 4.677

9.  Betulinic acid chemosensitizes breast cancer by triggering ER stress-mediated apoptosis by directly targeting GRP78.

Authors:  Youli Cai; Yifeng Zheng; Jiangyong Gu; Shengqi Wang; Neng Wang; Bowen Yang; Fengxue Zhang; Dongmei Wang; Wenjun Fu; Zhiyu Wang
Journal:  Cell Death Dis       Date:  2018-05-25       Impact factor: 8.469

Review 10.  Metastatic and triple-negative breast cancer: challenges and treatment options.

Authors:  Sumayah Al-Mahmood; Justin Sapiezynski; Olga B Garbuzenko; Tamara Minko
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

View more
  3 in total

1.  The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer.

Authors:  Cheng-Wei Chou; Ri-Yao Yang; Li-Chuan Chan; Ching-Fei Li; Linlin Sun; Heng-Huan Lee; Pei-Chih Lee; Yuh-Pyng Sher; Haoqiang Ying; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2020-08-01       Impact factor: 6.166

2.  Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress.

Authors:  Xihui Liu; Suryavathi Viswanadhapalli; Shourya Kumar; Tae-Kyung Lee; Andrew Moore; Shihong Ma; Liping Chen; Michael Hsieh; Mengxing Li; Gangadhara R Sareddy; Karla Parra; Eliot B Blatt; Tanner C Reese; Yuting Zhao; Annabel Chang; Hui Yan; Zhenming Xu; Uday P Pratap; Zexuan Liu; Carlos M Roggero; Zhenqiu Tan; Susan T Weintraub; Yan Peng; Rajeshwar R Tekmal; Carlos L Arteaga; Jennifer Lippincott-Schwartz; Ratna K Vadlamudi; Jung-Mo Ahn; Ganesh V Raj
Journal:  Nat Cancer       Date:  2022-06-02

Review 3.  HSP70s in Breast Cancer: Promoters of Tumorigenesis and Potential Targets/Tools for Therapy.

Authors:  Alexander E Kabakov; Vladimir L Gabai
Journal:  Cells       Date:  2021-12-07       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.